1354-3784
Monthly
No
1744-7658
EXPERT OPIN INV DRUG
1994
117
ENGLAND
http://www.tandfonline.com/toc/ieid20/current
较慢,6-12周审稿时间
2区中科院分区
一般平均录用比例
4.1影响因子
药学小学科
79/352JIF RANK
5733总被引频次
月期刊平台服务过的文章录用时间为1-3个月,依据20年经验,经月期刊专家预审通过后的文章,投稿通过率100%以上!
由Informa Pharmaceutical Science出版(原Ashley Publications)。ISSN: 1354 - 3784。《研究药物专家意见》(EOID)是一份经同行评审的月刊,评估药物研究的进展,从动物研究到新药物的推出。鼓励作者对审查中的研究现状发表专家意见,而不是简单地审查现有数据。每期杂志还包括社论、药物评价、临床试验报告、会议纪要和论文评价。观众包括制药行业的科学家、经理和决策者,以及与研发密切相关的其他人。用户包括美国、欧洲和日本的大多数主要制药公司,以及许多生物技术公司。研究药物的专家意见采用系统的方法进行覆盖,每个问题都集中在一个主要的治疗领域。
https://mc.manuscriptcentral.com/eoid
Published by Informa Pharmaceutical Science (formerly Ashley Publications). ISSN: 1354-3784.Expert Opinion on Investigational Drugs (EOID) is a monthly peer-reviewed journal, evaluating developments in pharmaceutical research, from animal studies through to the launch of a new medicine. Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than simply reviewing the available data. Each issue of the journal also contains Editorials, Drug Evaluations, Clinical Trial Reports, Meeting Highlights and Paper Evaluations. The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Investigational Drugs adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas.
大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
医学 | 2区 | PHARMACOLOGY & PHARMACY 药学 | 2区 | 否 | 是 |
JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
Q1 | PHARMACOLOGY & PHARMACY | Q1 | 6.498 |
CiteScore | SJR | SNIP | 学科类别 | 分区 | 排名 | 百分位 |
8.60 | 1.177 | 1.056 | 大类:Medicine 小类:Pharmacology (medical) | Q1 | 22 / 255 |
91% |
大类:Medicine 小类:Pharmacology | Q1 | 48 / 303 |
84% |
影响因子 | h-index | Gold OA文章占比 | 研究类文章占比 | OA开放访问 | 平均审稿速度 |
6.498 | 94 | 10.13% | 38.14% | 未开放 | 较慢,6-12周 |